MA30581B1 - Vaccin viral recombinant - Google Patents
Vaccin viral recombinantInfo
- Publication number
- MA30581B1 MA30581B1 MA31557A MA31557A MA30581B1 MA 30581 B1 MA30581 B1 MA 30581B1 MA 31557 A MA31557 A MA 31557A MA 31557 A MA31557 A MA 31557A MA 30581 B1 MA30581 B1 MA 30581B1
- Authority
- MA
- Morocco
- Prior art keywords
- recombinant viral
- viral vaccine
- relates
- present
- viral vectors
- Prior art date
Links
- 229960004854 viral vaccine Drugs 0.000 title abstract 2
- 239000013603 viral vector Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne de nouveaux vaccins viraux recombinants. En particulier, la présente invention concerne des produits combinés qui contiennent des vecteurs viraux recombinants et des composés spécifiques susceptibles d'améliorer la réponse immunitaire suscitée in vivo par lesdits vecteurs viraux recombinants.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06360028 | 2006-06-20 | ||
US85296406P | 2006-10-20 | 2006-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30581B1 true MA30581B1 (fr) | 2009-07-01 |
Family
ID=38657260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31557A MA30581B1 (fr) | 2006-06-20 | 2009-01-09 | Vaccin viral recombinant |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100129403A1 (fr) |
EP (1) | EP2029169A2 (fr) |
JP (1) | JP2009541236A (fr) |
KR (1) | KR101141333B1 (fr) |
CN (1) | CN101472610A (fr) |
AU (1) | AU2007263281B2 (fr) |
BR (1) | BRPI0713711A2 (fr) |
CA (1) | CA2656266C (fr) |
CR (1) | CR10571A (fr) |
IL (1) | IL195683A0 (fr) |
MA (1) | MA30581B1 (fr) |
MX (1) | MX2008016036A (fr) |
NO (1) | NO20090194L (fr) |
RU (1) | RU2453335C2 (fr) |
WO (1) | WO2007147529A2 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG178254A1 (en) | 2009-08-07 | 2012-03-29 | Transgene Sa | Composition for treating hbv infection |
WO2012145577A1 (fr) * | 2011-04-20 | 2012-10-26 | Merial Limited | Vaccin antirabique avec adjuvant à profil de viscosité amélioré |
TWI575070B (zh) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Hbv聚合酶突變體 |
TW201318637A (zh) | 2011-09-29 | 2013-05-16 | Transgene Sa | 免疫療法組成物及用於治療c型肝炎病毒感染之療程(一) |
WO2013045668A2 (fr) | 2011-09-29 | 2013-04-04 | Transgene Sa | Composition et schéma immunothérapeutique de traitement d'une infection par le virus de l'hépatite c |
JP6333814B2 (ja) | 2012-07-10 | 2018-05-30 | トランジェーヌ、ソシエテ、アノニムTransgene S.A. | マイコバクテリア抗原ワクチン |
CN103409451A (zh) * | 2013-06-28 | 2013-11-27 | 扬州维克斯生物科技有限公司 | 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法 |
JP6605480B2 (ja) | 2014-01-09 | 2019-11-13 | トランスジェン・ソシエテ・アノニム | ヘテロオリゴマーマイコバクテリア抗原の融合物 |
US10555981B2 (en) | 2014-07-16 | 2020-02-11 | Transgene S.A. | Oncolytic virus for expression of immune checkpoint modulators |
US20190134190A1 (en) | 2016-05-04 | 2019-05-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
EP3522920A2 (fr) | 2016-10-10 | 2019-08-14 | Transgene SA | Polythérapie à base d'un produit immunothérapeutique et de modulateurs de mdsc |
WO2018091680A1 (fr) | 2016-11-18 | 2018-05-24 | Transgene Sa | Vecteurs oncolytiques à base de la variole bovine |
CN110168092A (zh) | 2016-12-28 | 2019-08-23 | 特朗斯吉有限公司 | 溶瘤病毒和治疗分子 |
WO2019020543A1 (fr) | 2017-07-28 | 2019-01-31 | Transgene Sa | Virus oncolytiques exprimant des agents ciblant des modulateurs immunitaires métaboliques |
WO2020011754A1 (fr) | 2018-07-09 | 2020-01-16 | Transgene | Virus de la vaccine chimériques |
US20220290179A1 (en) | 2019-08-29 | 2022-09-15 | Astellas Pharma Inc. | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
EP4178605A1 (fr) | 2020-07-13 | 2023-05-17 | Transgene | Traitement de la dépression immunitaire |
WO2023213763A1 (fr) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus codant pour un agent de liaison comprenant un sdab anti-pd-l1 |
WO2023213764A1 (fr) | 2022-05-02 | 2023-11-09 | Transgene | Polypeptide de fusion comprenant un anti-pd-l1 sdab et un membre du tnfsf |
WO2024003353A1 (fr) | 2022-07-01 | 2024-01-04 | Transgene | Protéine de fusion comprenant une protéine d tensioactive et un élément de la tnfsf |
WO2024038175A1 (fr) | 2022-08-18 | 2024-02-22 | Transgene | Poxvirus chimériques |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
DK0385630T3 (da) | 1989-02-27 | 1997-05-12 | Riker Laboratories Inc | 1H-imidazo(4,5-c)quinolin-4-aminer som antivirale midler |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
KR100242671B1 (ko) | 1991-03-07 | 2000-03-02 | 고돈 에릭 | 유전학적으로 처리한 백신 균주 |
GB9105383D0 (en) * | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US6331539B1 (en) * | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
DE60022665T2 (de) | 1999-09-25 | 2006-06-22 | Coley Pharmaceutical Gmbh | Immunstimulierende nukeinsäuren |
GB0023008D0 (en) * | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
EE05680B1 (et) | 2000-11-23 | 2013-10-15 | Bavarian Nordic A/S | Muundatud vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ning vaktsiin |
WO2003094836A2 (fr) | 2001-10-12 | 2003-11-20 | University Of Iowa Research Foundation | Methodes et produits permettant d'ameliorer des reponses immunitaires a l'aide de compose d'imidazoquinoline |
ATE491471T1 (de) * | 2002-03-19 | 2011-01-15 | Powderject Res Ltd | Adjuvantien für dns impstoffe basierend auf imidazochinoline |
WO2005018574A2 (fr) * | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Combinaisons et traitements immunostimulatoires |
EP1804583A4 (fr) * | 2004-10-08 | 2009-05-20 | 3M Innovative Properties Co | Adjuvant pour vaccin a adn |
-
2007
- 2007-06-15 AU AU2007263281A patent/AU2007263281B2/en not_active Ceased
- 2007-06-15 WO PCT/EP2007/005303 patent/WO2007147529A2/fr active Application Filing
- 2007-06-15 KR KR1020087030973A patent/KR101141333B1/ko not_active IP Right Cessation
- 2007-06-15 JP JP2009515748A patent/JP2009541236A/ja not_active Ceased
- 2007-06-15 EP EP07764675A patent/EP2029169A2/fr not_active Withdrawn
- 2007-06-15 RU RU2009101387/15A patent/RU2453335C2/ru not_active IP Right Cessation
- 2007-06-15 MX MX2008016036A patent/MX2008016036A/es active IP Right Grant
- 2007-06-15 US US12/306,227 patent/US20100129403A1/en not_active Abandoned
- 2007-06-15 CN CNA2007800232312A patent/CN101472610A/zh active Pending
- 2007-06-15 BR BRPI0713711-7A patent/BRPI0713711A2/pt not_active IP Right Cessation
- 2007-06-15 CA CA2656266A patent/CA2656266C/fr not_active Expired - Fee Related
-
2008
- 2008-12-03 IL IL195683A patent/IL195683A0/en unknown
-
2009
- 2009-01-09 MA MA31557A patent/MA30581B1/fr unknown
- 2009-01-13 NO NO20090194A patent/NO20090194L/no not_active Application Discontinuation
- 2009-01-16 CR CR10571A patent/CR10571A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20090194L (no) | 2009-03-10 |
MX2008016036A (es) | 2009-04-07 |
KR101141333B1 (ko) | 2012-05-23 |
CA2656266A1 (fr) | 2007-12-27 |
KR20090016719A (ko) | 2009-02-17 |
JP2009541236A (ja) | 2009-11-26 |
WO2007147529A3 (fr) | 2008-02-28 |
CA2656266C (fr) | 2012-07-31 |
AU2007263281B2 (en) | 2012-12-06 |
CR10571A (es) | 2009-05-14 |
AU2007263281A1 (en) | 2007-12-27 |
EP2029169A2 (fr) | 2009-03-04 |
IL195683A0 (en) | 2011-08-01 |
BRPI0713711A2 (pt) | 2012-10-30 |
CN101472610A (zh) | 2009-07-01 |
RU2453335C2 (ru) | 2012-06-20 |
RU2009101387A (ru) | 2010-07-27 |
US20100129403A1 (en) | 2010-05-27 |
WO2007147529A2 (fr) | 2007-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30581B1 (fr) | Vaccin viral recombinant | |
EA201001491A1 (ru) | Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов | |
AU2009326524A8 (en) | Use of Flt3 ligand for strengthening immune responses in RNA immunization | |
MX2009001412A (es) | Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas. | |
WO2009026465A3 (fr) | Composition et procédés de fabrication et d'utilisation de protéines de la grippe | |
MX2008009929A (es) | Vacuna a base de levadura para inducir una respuesta inmune. | |
IL214460A0 (en) | Malaria prime/boost vaccines | |
WO2009156405A8 (fr) | Nouveaux composés immunoadjuvants à base de flagelline et leur utilisation | |
HK1120730A1 (en) | Nipah virus vaccines nipah | |
CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
WO2006073431A3 (fr) | Genes du virus de la fievre aphteuse exprimant des recombines avipox | |
EP1594536A4 (fr) | Vaccin contre la grippe contenant un adjuvant | |
WO2007095318A3 (fr) | antigenes de la grippe, compositions de vaccins et procedes associes | |
MY169837A (en) | Immunogenic compositions of staphylococcus aureus antigens | |
GB2386072A (en) | Novel vaccine | |
MX2009004862A (es) | Estabilizacion de vacunas por liofilizacion. | |
MX352478B (es) | Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada. | |
UY33297A (es) | Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas | |
MX2011007692A (es) | Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion. | |
WO2007008918A3 (fr) | Vaccins de virus comprenant des proteines immunomodulatrices reliees a une enveloppe, et methode d'utilisation associee | |
MX2010006984A (es) | Vacunas contra la malaria. | |
WO2008048344A3 (fr) | Antigènes de bacillus anthracis, compositions pour vaccins et procédés connexes | |
WO2007046839A3 (fr) | Nouveaux vaccins a base de virus vivant | |
GB2439259A (en) | Vaccine against burkholderia infections | |
MX2007002659A (es) | Composicion vacunal contra el virus de la hepatitis c. |